From the moment your doctor prescribes Optune, the nCompass support program will be there for you on your Optune treatment journey.
If you would like to speak to an Optune Expert, you can contact us via phone or email below.
nCompass can help you navigate insurance coverage and financial assistance
Our experienced team has helped numerous patients and caregivers, in all different financial situations, get access to Optune. They may be able to help you by:
Working with your insurance provider to obtain coverage for Optune
Talking to you about financial assistance programs, which may be able to lower the cost of Optune therapy
Offering assistance through our Charitable Care Program, if your household income is less than $150,000. Certain conditions apply
nCompass will contact you to set up in-person training with a Device Support Specialist (DSS)
To help you get off to the right start, a DSS will come to your home* or doctor’s office to provide training to you and your caregivers on:
How to use the device
How to prepare your head
How to properly place transducer arrays
How to incorporate Optune into your life and daily activities
nCompass provides ongoing support from your DSS, 24/7 technical support, and travel assistance
Your DSS will provide ongoing support by:
Checking in and continuing to answer questions about using Optune
Working with you to obtain your monthly compliance data. This is a record of how much time during the day you are actively receiving therapy
Technical support is available 24/7 to:
Provide additional supplies, like extra batteries or transducer arrays
Help troubleshoot the device and answer technical questions
If your doctor tells you that it is okay, travel may be possible with Optune. Contact nCompass for:
Assistance if you plan to travel with Optune
If you’re preparing for air travel† with Optune, nCompass can work with you and your airline to make things go more smoothly
*Some circumstances may require device training to occur at another location.
†International travel support from nCompass is dependent on Optune’s approval status in the destination country.
Find out about national and local
The Buddy Program can connect you with patients and caregivers who have used Optune and know what it’s like.Connect now
Optune is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.
If you have newly diagnosed GBM, Optune is used together with a chemotherapy called temozolomide (TMZ) if:
If your tumor has come back, Optune can be used alone as an alternative to standard medical therapy if:
Optune is not for everyone. Talk to your doctor if you have:
Do not use Optune if you are pregnant or are planning to become pregnant. It is not known if Optune is safe or effective during pregnancy.
Optune should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure™, the maker of Optune.
Most common side effects of Optune when used together with chemotherapy (temozolomide, or TMZ) were low blood platelet count, nausea, constipation, vomiting, tiredness, scalp irritation from the device, headache, seizure, and depression.
The most common side effects when using Optune alone were scalp irritation (redness and itchiness) and headache. Other side effects were malaise, muscle twitching, fall and skin ulcers.
Talk to your doctor if you have any of these side effects or questions.
Please click here to see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.
On this site, patient and healthcare professional videos as well as all images labeled as Optune users, caregivers, or healthcare professionals depict actual patients, caregivers, and healthcare professionals. All other depictions of patients and caregivers are actor portrayals.
Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).